Iovance Biotherapeutics Director Wayne Rothbaum disclosed the purchase of 10M shares at a price of $6.50. The $65M of shares were purchased on December 2. Rothbaum now owns 18,067,333 shares of Iovance, which is up 10% to $7.49 in after-hours trading following the disclosure in a regulatory filing.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IOVA:
- Iovance Biotherapeutics to Present at Upcoming Conferences
- Iovance Biotherapeutics Tanks as FDA Requests More Data for Lifileuel
- Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
- Society for Immunotherapy of Cancer to hold a meeting
- Iovance Biotherapeutics announces updated clinical data for lifileucel
